Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the shareholders, including Bridgepoint, in FCG Group AB in connection with the divestment to IK Partners
Mandate

Vinge advises the shareholders, including Bridgepoint, in FCG Group AB in connection with the divestment to IK Partners

January 19, 2022 M&A Banking and Finance

FCG is a GRC services provider, offering advisory, outsourcing, GRC technology and fund administration services to the financial services industry.

Founded in 2008 and headquartered in Stockholm, Sweden, FCG has evolved to become a leading Nordic GRC player. FCG is serving a diversified customer base ranging from fast-growing fintech start-ups to large banks.

The transaction is subject to applicable regulatory approvals.

Vinge’s team consisted of Daniel Rosvall, Samra Baytar, Per Kling, Linnea Petersson and Caroline Krassén.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026